911
Views
0
CrossRef citations to date
0
Altmetric
Festschrift

Antimicrobial-resistant gonorrhoea in Africa: An important public health threat in need of a regional gonococcal antimicrobial surveillance programme

Pages 215-220 | Published online: 15 Jul 2015

References

  • World Health Organization. Prevalence and incidence of selected sexually transmitted infections. Geneva: World Health Organization, 2011
  • Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect 2010; 86:415–421
  • Martin JE, Jr, Lester, Price EV, Schmale JD. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955-1969. J Infect Dis 1970; 122: 459–461
  • Percival A, Rowlands J, Corkill JE, et al. Penicillinase-producing gonococci in Liverpool. Lancet 1976; 2:1379–1382
  • Centers for Disease Control and Prevention. Penicillinase-producing Neisseria gonorrhoeae. MMWR 1976; 33: 408–410
  • Fayemiwo SA, Muller EE, Gumede L, Lewis DA. Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011; 38: 329–333.
  • Roberts MC, Wagenvoort JH, Van Iff ingeren B, Knapp JS. tetM- and beta-lactamase-containing Neisseria gonorrhoeae (tetracycline resistant and penicillinase producing) in The Netherlands. Antimicrob Agents Chemother 1988; 32: 158
  • Tetracycline-resistant Neisseria gonorrhoeae - Georgia, Pennsylvania, New Hampshire. MMWR 1985; 34:563-564, 9–70
  • Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinompin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272–278
  • Brown LB, Knisiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37:169–172
  • Fekete T. Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy. Clin Microbial Rev 1993; 6:22–33
  • Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997; 8:299–302
  • Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, Howe RA, lson CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64: 353–358
  • Gransden WR, Warren CA, Phillips I, Hodges M, Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990; 335:51
  • Lewis DA. Antibiotic-resistant gonococci — past, present and future. S Afr Med J 2007; 97:1146–1150
  • Lewis DA, Scott L, Slabbed M, et al. Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity. Sex Transm Infect 2008; 84: 352–355
  • Moodley P, Sturm A. Ciprofloxacin-resistant gonorrhoea in South Africa. Lancet 2005; 366:1159
  • Ito M, Yasuda M, Yokoi S, et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 2004; 48:3185–3187
  • Deguchi T, Yasuda M, Yokoi S, et al.Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9:35–39
  • Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseda gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7:821–834
  • Tapsall JW. Implications of current recommendations for third-generation cephalosporins use in the WHO Western Pacific region following the emergence of multi-resistant gonococci. Sex Transm Infect 2009; 85: 256–258
  • World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006–2015: breaking the chain of transmission. Geneva: World Health Organization, 2007